💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, and…
A weak business.
Lasa Supergenics is scored on the pharma / healthcare framework. It keeps a thin -134.5% of every rupee of sales as net profit. Free cash flow is worth about -25.9% of its market value.
Net worth has actually shrunk (-25%/yr) — value is not being built. Return on equity is a weak -26.3%.
It trades at -2× earnings. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | -1.72 | 7.37 | better |
| P/B | 0.57 | — | — |
| EV/EBITDA | — | 17.46 | — |
| ROE | -26.3 | — | — |
| ROCE | -22.21 | 6.36 | worse |
| ROA | -24.96 | — | — |
| Quick Ratio | 0.51 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 35.8 | 5.2 | 13.7% |
| Divis Laboratories | 84.4 | 14.7 | 15.3% |
| Torrent Pharmaceuticals | 84.0 | 21.5 | 25.5% |
Revenue declined 83% in the latest year — a break from prior trajectory. Negative CAGR — the top line has shrunk over this window. Growth is decelerating — latest year grew slower than the year before.
4 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -131% swing — check if it's a one-off or structural.
Operating margin has compressed from -32% to -137% — costs or competition are eating into profitability.
Negative ROE — the business is destroying shareholder value. Capital efficiency declining — ROE down 36pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play.
3 of 4 years had negative operating cash flow — profitability on paper may not translate to cash.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 1578% sequentially — momentum is building. Wide quarterly swings (103% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate fading — recent quarters 77% below earlier ones.
4 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 14% QoQ — check if this is operating leverage or a one-off item. Quarterly margins are compressing (-204% → -269%) — more revenue isn't translating to proportionally more profit.
P/E band unavailable — needs 5y of consistent EPS + price history.
Promoter holding at 53.6% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.